Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
Mross
K
K
Tumor Biology Center, Albert-Ludwigs-University Freiburg, Germany. mross@tumorbio.uni-freiburg.de
Steinbild
S
S
Baas
F
F
Reil
M
M
Buss
P
P
Mersmann
S
S
Voliotis
D
D
Schwartz
B
B
Brendel
E
E
D000284:Administration, Oral; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D001557:Benzenesulfonates / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D006801:Humans; D000077146:Irinotecan; D009369:Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D019908:Proto-Oncogene Proteins c-raf / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D000077157:Sorafenib
D000972:Antineoplastic Agents, Phytogenic; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077146:Irinotecan; D000077157:Sorafenib; D019908:Proto-Oncogene Proteins c-raf; D002166:Camptothecin